

NATIONAL PATIENT GROUP DIRECTION FOR URGENT PROVISION OF MEDICINES, APPLIANCES AND ACBS PRODUCTS.

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS.

IT IS THE RESPONSIBILITY OF THE INDIVIDUAL TO ENSURE THEY ARE USING THE MOST UP TO DATE PGD

1

1. Authorisation

Developed on behalf of NHS Scotland by NHS 24 by:

Physician	Dr Laura Ryan	Signature	Laure	42
Pharmacist	Dr John McAnaw	Signature	John	44m
NHS Scotland Representative	Mr Jim Miller	Signature	fu	h.lles
Authorised for use	on behalf of			Health Board by
Medical Director		Signature		
Senior Pharmacist		Signature		
Clinical Governance Lead		- Signature -		
Date Approved				
Effective from			Expires	



2. Management of the Patient Group Direction (PGD)

This PGD must be read, agreed to and signed by all pharmacists involved in its use. The original signed copy should be held by the Health Board.

3. Application

This PGD covers the urgent provision of current NHS prescribed medicines, appliances and ACBS products to NHS patients by pharmacists where there is a clinical need, it is clinically appropriate to make the supply and when the patient's prescriber is unavailable.

4. Clinical Condition

Situation	The provision from a pharmacy with an NHS contract of NHS prescribed medicines, appliances and ACBS products required when the patient is unable to obtain a prescription for supply in the normal way for the clinical conditions described in part A in the schedules of this PGD.	
Inclusion Criteria	Medicines and/or appliances and/or ACBS products requested by patient and are currently being prescribed by patient's prescriber (see Note 1).	
	Medicines and/or appliances and/or ACBS products are allowed on NHS prescription and are not listed in part B in the schedules of this PGD.	
	The prescriber is unavailable.	
	Patient is registered (or temporarily) with a medical practice in Scotland.	
	Patient agrees to relevant clinical information being provided to the pharmacist.	
	Patient agrees that all relevant clinical information is shared between their prescriber and the pharmacist.	
Exclusion Criteria	Provision is not urgent.	
	Medicines and/or appliances and/or ACBS products which are listed in part B in the schedules of this PGD or are not allowed on NHS prescription.	
	No agreement to share relevant clinical information.	
	Patient's clinical condition significantly changed.	
Action if Excluded	Provide supply under existing emergency supply regulations.	
	Refer to prescriber or to OOH service using the direct referral process if emergency supply regulations do not apply.	



Note 1

The PGD not only covers the urgent supply of a repeat prescription item, but permits the supply of a medicine in a number of other situations thereby bringing it into line with current emergency supply regulations. Below are some scenarios where an urgent supply can be given supporting continuity of patient care (not an exhaustive list):

- Patient recently discharged from hospital with new medication and has not organised a further supply of medication with their own prescriber who is now unavailable
- Acute prescribed medication that has been lost, stored incorrectly, or smashed bottle
- Medication that is prescribed regularly but may not be on a repeat prescription for example antidepressants
- Patient has been prescribed an acute medication, but prescription has not been forwarded/received in the pharmacy and prescriber unavailable – information held on Emergency Care Summary (ECS) obtained directly by the pharmacy or through NHS 24 would enable supply *
- Patient prescribed medication which they cannot swallow, and they require a liquid preparation
- Alternative flavour of same antibiotic if child unable to tolerate dispensed medication, or indeed capsule or tablet formulation if this resolves the situation
- Supply alternative formulation if dispensed medication is not suitable for other reasons e.g. allergy to excipient, religious reason e.g. beef gelatine
- Acute supplies of rescue antibiotic for COPD patients, many patients keep rescue antibiotic prescription but may have used the last one without renewing it
- Dispense remaining balance of antibiotic when original dispensing pharmacy is closed

^{*} If you are unable to access ECS, then please contact your Health Board to have this rectified. Details of individual Health Boards can be found on the NHS Community Pharmacy website via the following link contact your Health Board. There is also guidance on accessing/troubleshooting ECS on the Community Pharmacy Scotland (cps.scot) website.



5. Description of Treatment

Medicine	All medicines and/or appliances and/or ACBS products required and listed in BNF and BNFC described in part A in the schedules of this PGD.	
Legal Status	As described in the BNF or BNFC.	
Dosage Form and Strength	As normally prescribed by the patient's prescriber.	
	Or	
	Variation of product brand and/or dosage form and/or strength may be substituted when usual product cannot be supplied within a reasonable time provided the active drug base and dose and dosage regimen is equivalent.	
Dose	As normally prescribed by the patient's prescriber or if not known as recommended by the BNF or BNFC.	
Exceptions	All medicines and/or appliances and/or ACBS products listed in part B in the schedules of this PGD.	
Duration of Supply	One prescribing cycle i.e. quantity and duration normally prescribed to patient or up to one month's supply if not known.	
Patient Information	Provision of the appropriate Pharmaceutical Industry Patient Information Leaflet.	
	Provision of any other relevant information as judged by the pharmacist operating under this PGD.	
Documentation	The pharmacist will complete a Universal Claim Framework (UCF) entry within the patient's PMR, producing a completed CP4 form detailing the supply made.	
Supply	The supply of medicine and/or appliances and/or ACBS products should comply with the requirement for labelling and be in an appropriate container or packaging.	
Follow-up	Ensure that the patient's prescriber is notified and that all records are completed.	
Adverse reactions	As described in BNF or BNFC.	



Record/Audit Trail	The UCF electronic claim is automatically forwarded to NHS NSS for processing	
	A record of the transaction i.e. CP4 form print out, should be forwarded to the patient's prescriber as soon as possible for information.	
	A record of the transaction should automatically be entered in the patient's Prescription Medication Record.	

6. Characteristic of Staff

Qualifications	Pharmacist whose name is currently on the practising section of
Required	the pharmaceutical register held by the General Pharmaceutical
	Council (GPhC).



SCHEDULE 1

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Gastro-intestinal system, chapter 1

Part A: All medicines in Gastro-intestinal system, chapter 1 of the current BNF/BNFC ¹, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Chronic bowel disorders	Food allergy	Rectal and anal disorders
Constipation ² and bowel cleansing Diarrhoea	Gastro-intestinal smooth muscle spasm Liver disorders and related	Exocrine pancreatic insufficiency Stoma care
	conditions	
Gastric acid disorders and ulceration	Obesity	

Part B: The following medicines listed in Gastro-intestinal system, chapter 1 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale	
All injections and infusions	Acute/Specialist use only	
All section 2.1	Acute use only	
Chenodeoxycholic Acid	Specialist use only	
Cholic Acid	Specialist use only	
Obeticholic acid	Specialist use only	
Odevixibat	Specialist use only	
Opium	Specialist use only/controlled drug	

¹ Supply of azathioprine, ciclosporin, mercaptopurine and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page14)

² Supply of sodium citrate products for treating constipation is allowed under this section of the PGD



SCHEDULE 2

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Cardiovascular system, chapter 2

Part A: All medicines in Cardiovascular system, chapter 2 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Arrhythmias	Blood pressure conditions	Myocardial ischaemia
Bleeding disorders	Heart failure	Oedema
Blood clots	Hyperlipidaemia	Vascular disease

Part B: The following medicines listed in Cardiovascular system, chapter 2 of the current BNF/BNFC may NOT be provided under this PGD.

Excluded drug	Rationale
All injections, infusions and intravenous	Acute/Specialist use only
flushes except:	
injections for self-administration:	
Evolocumab	
Bemiparin sodium	
Dalteparin sodium	
Enoxaparin sodium	
Tinzaparin sodium	
All section 2.1	Specialist use only
All section 2.2	Acute/Specialist use only
All section 4.1a	Specialist use only
All section 4.1c	Specialist use only
All section 4.2 except : Midodrine HCl	Specialist use only
Vericiguat	Hospital use only
Lomitapide	Specialist use only
Mexiletine	Specialist use only



SCHEDULE 3

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Respiratory system, chapter 3

Part A: All medicines in Respiratory system, chapter 3 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Airways disease, obstructive	Conditions affecting sputum viscosity
Allergic Conditions ³	Cough and congestion

Part B: The following medicines listed in Respiratory system, chapter 3 of the current BNF/BNFC may NOT be provided under this PGD.

Excluded drug	Rationale	
All injections ³ and infusions	Acute/Specialist use only	
All section 3.1 except:	Specialist/Hospital use only	
Dornase alfa		
All section 5	Specialist/Hospital use only	
Berotralstat	Hospital use only	
Erdosteine	Acute use only	
Grass pollen extract	Specialist use only	
House dust mite extract	Specialist use only	
Peanut protein	Specialist use only	
Oxygen ⁴	Alternative supply route	

³ Supply of adrenaline (Emerade® EpiPen® Jext®) for self-administration to treat anaphylaxis is allowed under this schedule of the PGD

⁴ Oxygen supplies should be obtained via Dolby Vivisol on 0800 833 531



SCHEDULE 4

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Nervous system, chapter 4

Part A: All medicines in Nervous system, chapter 4 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Dementia	Nausea and labyrinth disorders	Sleep disorders
Mental health disorders	Pain	Substance dependence
Movement disorders	Epilepsy and Other Seizure disorders 5	

Part B: The following medicines listed in Nervous system, chapter 4 of the current BNF/BNFC may NOT be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 3.2 except; Atomoxetine, Guanfacine	Controlled drug
All section 8.3	Controlled drug/Specialist use
Aprepitant	Specialist use only
Buprenorphine	Controlled drug
Cannabidiol	Specialist use only
Capsaicin patches	Specialist use only
Clobazam ⁶	Epilepsy only
Clozapine ⁷	Registration required
Codeine phosphate oral solution	Potential for abuse
Dipipanone hydrochloride with cyclizine	Controlled drug
Fenfluramine	Specialist use only
Fentanyl	Controlled drug
Gabapentin	Controlled drug
Hydromorphone hydrochloride	Controlled drug
Loxapine	Specialist/Hospital use only
Methoxyflurane	Close medical supervision only
Midazolam ⁸	Controlled drug
Morphine ⁹	Controlled drug
Morphine with cyclizine	Controlled drug
Nabilone	Controlled drug/Hospital Use
Oxycodone Hydrochloride	Controlled drug
Oxycodone with naloxone	Controlled drug
Palonosetron	Specialist use only
Palonosetron with netupitant	Specialist use only
Paracetamol with tramadol	Controlled drug

Unscheduled Care - Pharmacy Guide - PGD v30

Due for review April 2024

NOT FOR AMENDMENT.

from April 2023 – October 2024 Page 9 of 23



Pentazocine	Controlled drug
Pethidine hydrochloride	Controlled drug
Pregabalin	Controlled drug
Sodium Oxybate	Specialist use only
Solriamfetol	Hospital use only
Tapentadol	Controlled drug
Temazepam	Controlled drug
Tramadol	Controlled drug
Tryptophan	Specialist use only

⁵ Patients receiving therapy with Category 1 antiepileptics - phenytoin, carbamazepine, phenobarbital or primidone- should be maintained on their usual brand. Patients receiving therapy with Category 2 antiepileptics - the need for continued supply of a particular manufacturer's product should be based on clinical judgement, taking in to account factors such as seizure frequency and treatment history. (MHRA/CHM-Nov 2013)

⁶ Clobazam can be supplied under the PGD for epilepsy only and must be endorsed SLS.

⁷ Clozapine <u>can</u> be supplied under the PGD if the Pharmacy is registered for the patient monitoring service for that

⁸ Midazolam oromucosal solution can only be supplied under this PGD for the emergency treatment of **status epilepticus**

⁹ All strengths <u>are not</u> allowed on the PGD including oramorph 10mg/5ml



SCHEDULE 5

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Infections, chapter 5

Part A: All medicines in Infections, chapter 5 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Amoebic infection	Fungal infection	Nocturnal Leg Cramps
Bacterial infection	Viral infection	

Part B: The following medicines listed in Infections, chapter 5 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 1	Acute use only
All section 4	Acute use only
All section 5 except Quinine for	Acute use only
nocturnal leg cramps	
All section 6.1 except Molnupiravir for	Specialist use only
mild to moderate COVID-19	
All section 6.3a and 6.3b	Specialist use only
All section 6.6	Acute use only
Amikacin	Hospital use only
Fidaxomicin	Acute use only
Delafloxacin	Hospital use only
Isavuconazole	Hospital use only
Letermovir	Hospital use only
Linezolid	Specialist use only
Tedizolid	Acute use only
Neomycin	Acute use only
Posaconazole	Hospital use only
Rifaximin	Acute use only
Tobramycin	Acute use only
Vancomycin	Acute use only



SCHEDULE 6

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Endocrine system, chapter 6

Part A: All medicines in Endocrine, chapter 6 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Antidiuretic hormone disorders	Bone metabolism disorders	Sex hormone responsive conditions
Corticosteroid responsive conditions	Dopamine responsive conditions	Thyroid disorders
Diabetes mellitus and	Gonadotrophin responsive	
hypoglycaemia	conditions	

Part B: The following medicines listed in Endocrine system, chapter 6 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions except in	Acute/Specialist use only/Controlled
section 4	drug
Section 3.1	Specialist use only
All section 7	Specialist use only
All section 8.2 except section 8.2a	Controlled drug
lodide with iodine	Acute use only
Tolvaptan	Hospital use only



SCHEDULE 7

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Genito-urinary system, chapter 7

Part A: All medicines in Genito-urinary system, chapter 7 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Bladder and urinary	Erectile and ejaculatory
disorders	conditions
Contraception	Vaginal and vulval conditions

Part B: The following medicines listed in Genito-urinary system, chapter 7 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions except	Acute/Specialist use only
Section 3.5	
All intra-uterine devices	Time period between repeats
All section 2	Specialist use only
All section 3.2	Time period between repeats
All section 3.3	Acute use only
All section 6	Specialist use only



SCHEDULE 8

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Malignant disease, chapter 8

Part A: All medicines in Malignant disease, chapter 8 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Immune system ¹⁰	Malignant disease

Part B: The following medicines listed in Malignant disease, chapter 8 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All Immune System drugs excluded EXCEPT:	Acute/Specialist
	use only
Azathioprine (oral) for immunosuppression and the treatment of	
Crohn's disease, rheumatoid arthritis, Systemic Lupus Erythematosus,	
refractory eczema, myasthenia gravis Ciclosporin (oral) ¹⁰ for immunosuppression and the treatment of	
severe ulcerative colitis, severe RA, severe atopic dermatitis, severe	
psoriasis, nephrotic syndrome	
Sirolimus	
Tacrolimus (oral) 10	
Mycophenolate mofetil (oral)	
All Malignant Disease drugs excluded EXCEPT:	Specialist use
	only
Mercaptopurine (oral) for the treatment of Crohn's, ulcerative colitis	
Methotrexate (oral and subcutaneous injections for self-administration)	
for the treatment of severe Crohn's, severe rheumatoid arthritis, severe psoriasis	
Anastrazole	
Bicalutamide	
Diethylstibestrol	
Enzalutamide ¹¹	
Exemestane	
Flutamide	
Lanreotide	
Letrozole	
Megestrol	
Tamoxifen 10 Patients receiving oral therapy with ciclosporin or tacrolimus should be maintained on	

¹⁰ Patients receiving oral therapy with ciclosporin or tacrolimus should be maintained on their usual brand. Any change must be under the supervision of a specialist.

¹¹ Enzalutamide can be supplied under the PGD if the patient is within the required monitoring period



SCHEDULE 9

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Blood and nutrition, chapter 9

Part A: All medicines in Blood and nutrition, chapter 9 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Anaemias	Metabolic disorders	Mineral and trace elements deficiencies
Platelet disorders	Nutrition	Vitamin deficiency
Fluid and electrolyte imbalances		

Part B: The following medicines listed in Blood and nutrition, chapter 9 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale	
Blood and blood-forming organs		
All injections and infusions except:	Acute/Specialist use only	
section 1.1		
section 1.3		
All drugs in section 2	Specialist use only	
All drugs in section 3	Specialist use only	
All drugs in section 4	Specialist use only	
Nutrition and metabolic disorders		
All injections and infusions	Specialist use only	
section 1	Specialist use only	
section 3.4		
section 3.11		
section 3.13		
section 3.14		
section 6.1a		
Cinacalcet granules	Hospital use only	
Eliglustat	Specialist use only	
Migalastat	Specialist use only	
Oxymetholone	Controlled Drug	
Tafamidis	Hospital use only	
Voxelotor	Hospital use only	



SCHEDULE 10

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Musculoskeletal system, chapter 10

Part A: All medicines in Musculoskeletal, chapter 10 of the current BNF/BNFC ¹², with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Arthritis	Neuromuscular disorders
Hyperuricaemia and gout	Pain and inflammation in
	musculoskeletal disorders

Part B: The following medicines listed in Musculoskeletal, chapter 10 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 3.1	Hospital use only
Amifampridine	Specialist use only
Baricitinib	Specialist use only
Leflunomide 13	Monitoring required
Tofacitinib	Specialist use only
Filgotinib	Specialist use only
Upadacitinib	Specialist use only

¹² Supply of azathioprine, ciclosporin and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page 14)

¹³ Leflunomide can be supplied under the PGD if the patient is within the required monitoring period



SCHEDULE 11

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Eye, chapter 11

Part A: All medicines in Eye, chapter 11 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Allergic and inflammatory	Eye infections	Glaucoma and ocular
eye conditions		hypertension
Dry eye conditions	Eye procedures	

Part B: The following medicines listed in Eye, chapter 11 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 4 except:	Acute/Specialist use only
Bromfenac	
Diclofenac sodium	
Flurbiprofen	
Ketorolac trometamol	
All section 6	Specialist use only



SCHEDULE 12

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Ear, nose and oropharynx, chapter 12

Part A: All medicines in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Dry mouth	Oral hygiene	Oropharyngeal fungal infections
Nasal congestion	Otitis media	Oropharyngeal viral infections
Nasal inflammation, nasal polyps and rhinitis	Oral ulceration and inflammation	Otitis Externa
Nasal staphylococcal infection	Oropharyngeal bacterial infections	

Part B: The following medicines listed in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
Aluminium acetate	Acute use only



SCHEDULE 13

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Skin, chapter 13

Part A: All medicines in Skin, chapter 13 of the current BNF/BNFC ¹⁴, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Dry and scaling skin	Sun protection and	Skin cleansers, antiseptics
disorders	photodamage	and desloughing agents
Infections of the skin	Pruritus	Skin disfigurement
Inflammatory skin	Rosacea and acne	Superficial soft tissue
conditions		injuries and superficial
		thrombophlebitis
Perspiration	Scalp and hair conditions	Warts and calluses

Part B: The following medicines listed in Skin, chapter 13 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
Abrocitinib	Hospital use only
Alitretinoin	Specialist use only
Isotretinoin	Specialist use only

¹⁴ Supply of azathioprine, ciclosporin and methotrexate to treat a condition listed in Section A above is allowed under this section of the PGD (see PGD page 14)



SCHEDULE 14

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Vaccines, chapter 14

Part A: All medicines in Vaccines, chapter 14 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

There are no clinical conditions.

Part B: The following medicines listed in Vaccines, chapter 14 of the current BNF/BNFC **may not** be provided under this PGD.

Excluded drug	Rationale
All chapter 14	Acute/Specialist use only



SCHEDULE 15

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Anaesthesia, chapter 15

Part A: All medicines in Anaesthesia, chapter 15 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Local anaesthesia

Part B: The following medicines listed in Anaesthesia, chapter 15 of the current BNF/BNFC **may not** be provided under this PGD.

Excluded drug	Rationale
All chapter 15 except :	Acute/Specialist use only
Lidocaine hydrochloride cream, ointment, plaster and spray	
Lidocaine with prilocaine cream	
Tetracaine gel	



SCHEDULE 16

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Emergency treatment of poisoning, chapter 16

Part A: All medicines in Emergency treatment of poisoning, chapter16 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, **may** be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

Management of opioid overdose	

Part B: The following medicines listed in Emergency treatment of poisoning, chapter 16 of the current BNF/BNFC **may not** be provided under this PGD.

Excluded drug	Rationale
All chapter 16 except:	Acute/Specialist use only
Naloxone hydrochloride	



SCHEDULE 17

PATIENT GROUP DIRECTION FOR THE URGENT PROVISION OF CURRENT PRESCRIBED MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS

BNF/BNFC Class of Medicine: Borderline Substances, appendix 2

Part A: All products in the Borderline Substances section, appendix 2 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions: ¹⁵

Disease-related malnutrition	Intractable malabsorption	Pre-operative preparation of malnourished patients
Dysphagia	Proven inflammatory bowel disease	Following total gastrectomy
Short-bowel syndrome	Bowel fistula	Photodermatoses (skin protection in)
Dermatitis, eczema and pruritis	Disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitiligo	Dry mouth (xerostomia)

Part B: The following medicines listed in Borderline Substances, appendix 2 of the current BNF/BNFC may not be provided under this PGD.

There are no exclusions

¹⁵ All items supplied from this section under the PGD **must be endorsed ACBS.** If required, refer to Scottish Drug Tariff section 16 for current list of allowable gluten-free products